- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02097719
Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
December 9, 2015 updated by: Allergan
This efficacy and safety study will evaluate LUMIGAN® .01
(bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL GFS, 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Racine, Wisconsin, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ocular hypertension or glaucoma that requires treatment with medication
- Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes
Exclusion Criteria:
- History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
- History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
- Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: bimatoprost 0.01% and hypromellose 0.3%
Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
|
Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
Other Names:
Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
Other Names:
|
Active Comparator: travoprost 0.004% and timolol 0.5%
Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
|
Timolol 0.5% administered to both eyes once daily for 12 weeks.
Other Names:
Travoprost 0.004% administered to both eyes once daily for 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM
Time Frame: Week 12 at 8 AM, 12 PM, and 4 PM
|
IOP is a measurement of the fluid pressure inside the eye.
IOP of the study eye (worse eye) is measured at 8 AM, 12 PM, and 4 PM.
IOP is either the average of 2 measurements, or, if a third measurement is required, the average of 3 measurements.
|
Week 12 at 8 AM, 12 PM, and 4 PM
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2014
Primary Completion (Actual)
December 1, 2014
Study Completion (Actual)
December 1, 2014
Study Registration Dates
First Submitted
March 25, 2014
First Submitted That Met QC Criteria
March 25, 2014
First Posted (Estimate)
March 27, 2014
Study Record Updates
Last Update Posted (Estimate)
January 14, 2016
Last Update Submitted That Met QC Criteria
December 9, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Glaucoma
- Ocular Hypertension
- Hypertension
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Timolol
- Travoprost
- Bimatoprost
Other Study ID Numbers
- GMA-LUM-12-022
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Hypertension
-
Western Galilee Hospital-NahariyaUnknown
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria
-
Santen Inc.Completed
-
West Virginia UniversityUniversity of PittsburghRecruitingGlaucoma and Ocular HypertensionUnited States, United Kingdom, Canada
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
Santen Inc.Completed
-
Maastricht University Medical CenterCompletedCorticosteroid Induced Ocular Hypertension/GlaucomaNetherlands
-
Santen Inc.CompletedA Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTGlaucoma and Ocular HypertensionUnited States
-
Bausch & Lomb IncorporatedCompletedGlaucoma | Open Angle or Ocular HypertensionUnited States
-
Nicox Ophthalmics, Inc.CompletedGlaucoma, Open-Angle | Hypertension, OcularUnited States
Clinical Trials on bimatoprost 0.01%
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleKorea, Republic of
-
AllerganCompletedOcular Hypertension | Glaucoma, Primary Open AngleTaiwan
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
University of California, San DiegoCompletedOcular Hypertension | Glaucoma | Intraocular PressureUnited States
-
Northwestern UniversityAllerganCompletedIntraocular Pressure | Nail Growth CessationUnited States
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleNetherlands
-
AllerganCompletedA Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)Ocular Hypertension | Glaucoma, Open-AngleGermany
-
Amneal Pharmaceuticals, LLCCBCC Global Inc.; Amneal EU, LimitedNot yet recruitingOcular Hypertension | Open-angle GlaucomaUnited States
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleAustria
-
Amneal Pharmaceuticals, LLCCBCC Global ResearchRecruitingOcular Hypertension | Glaucoma, Open-AngleUnited States